ZENTALIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.87 USD | -0.84% |
|
+5.32% | -21.65% |
| 05-29 | Zentalis Pharmaceuticals Announces Appointment of Luke Walker, M.D., to Board of Directors | CI |
| 05-24 | Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial | MT |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Zentalis Data Review KOL...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.88
USD
Average target price
33.4
USD
Spread / Average Target
+181.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.65% | 850M | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
- Stock Market
- Equities
- ZNTL Stock
- News Zentalis Pharmaceuticals, Inc.
- Transcript : Zentalis Pharmaceuticals, Inc. - Special Call
